Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1/2 4Phase 1 4Phase 3 1Phase 2/3 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Tumor-Agnostic 1Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neoplasms 2Endometrial Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Specimen Handling 146pembrolizumab 120Magnetic Resonance Spectroscopy 117Cyclophosphamide 114Biopsy 97fludarabine 88Nivolumab 52Carboplatin 51Cisplatin 47Gemcitabine 46venetoclax 41Radiotherapy 41Paclitaxel 40Cetuximab 40fludarabine phosphate 39Ipilimumab 34atezolizumab 33Fluorouracil 33Bevacizumab 33Oxaliplatin 27Leucovorin 27Dexamethasone 27durvalumab 26X-Rays 25Irinotecan 25Radiation 24Cytarabine 24Azacitidine 24Injections 22Temozolomide 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × dostarlimab × 90 days × Clear all
NCT05819892 2026-05-29

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
21 enrolled
Gynecologic

Endometrial Neoplasms

NCT05277051 2026-05-22

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

GlaxoSmithKline

Phase 1 Active not recruiting
152 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06551142 2026-05-22

PanTumor-101

GlaxoSmithKline

Phase 1 Recruiting
845 enrolled
Tumor-Agnostic

Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

University of Southern California

Phase 1 Active not recruiting
10 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡